Allergy Therapeutics PLC

Company Profile

• Business description

  Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).

• Contact

  Dominion Way
  WorthingWest SussexBN14 8SA
  GBR

  T: +44 1903844700

  E: [email protected]

  https://www.allergytherapeutics.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - Specialty & Generic

  Fiscal Year End

  30 June 2026

  Employees

  576